Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine

NCT ID: NCT01316406

Last Updated: 2014-01-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 122 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2013-08-31

Brief Summary

The aim of this study is to evaluate the safety and efficacy of ATH008 cream in patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine therapy. In part I, the safety and plasmatic levels of the active ingredient and its metabolite will allow to determine the most appropriate and beneficial dose for the second part of the study. In Part II, the efficacy of ATH008 cream in reducing the number of patients presenting PPES grade 2/3 secondary to capecitabine therapy following a four times daily application will be tested.

Detailed Description

This is a Phase II Placebo Controlled, Multicenter Study that will involve up to 114 patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine therapy. Eligible patients will be enrolled into Part I or Part II of the study.

The first part of the study (Part I) is designed

• to demonstrate the safety of ATH008 cream 1%, 3% and 8% and ATH008 cream placebo,
• to determine the plasmatic levels of the active ingredient and its metabolite after repeated doses of ATH008 cream 1%, 3% and 8%, and
• to determine the grade of PPES at Day 1 and Day 21 of ATH008 cream treatment Part I will have four different arms; patients will receive one of the three different doses of drug product (ATH008 cream 1%, ATH008 cream 3% or ATH008 cream 8%) or placebo (ATH008 cream placebo) in repeated doses (twice daily) during a period of 21 days.

Patients will continue to be assessed for safety and pharmacokinetics of active ingredient and its metabolite (Pre-dose, Day 1 and Day 21). Results of Part I will determine the most appropriate and beneficial dose for the second part of the study.

The second part of the study (Part II) is aimed at demonstrating the safety and efficacy of ATH008 cream in reducing the number of patients presenting PPES grade 2/3 secondary to capecitabine therapy following a four times daily application.

Part II will have three different arms; patients will receive ATH008 cream 3%, 8% or placebo in repeated doses (four times per day) since appearance of PPES grade 1 until appearance of grade 2-3 or a maximum of 4 cycles. Patients will continue to be assessed for safety. The clinical signs will be reported by iconographic register of lesions and pain will be evaluated using a pain scale. Patient will fill a questionnaire reporting QoL.

Conditions

Palmar-Plantar Erythrodysesthesia Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

ATH008 cream 3%

ATH008 cream 3%

Group Type: EXPERIMENTAL

ATH008

Intervention Type: DRUG

The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo

ATH008 cream 8%

ATH008 cream 8%

Group Type: EXPERIMENTAL

ATH008

Intervention Type: DRUG

The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo

ATH008 cream placebo

ATH008 cream placebo

Group Type: PLACEBO_COMPARATOR

ATH008

Intervention Type: DRUG

The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo

Interventions

ATH008

The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo

Intervention Type: DRUG

Other Intervention Names

ATH008 cream

Eligibility Criteria

Inclusion Criteria

• Are under capecitabine monotherapy for treatment of colon or breast cancer at a regimen of 2 weeks on and 1 week off (14+7) and a daily doses between 2000 and 2500 mg/m2.
• Diagnosis of PPES grade 1 in any hand or foot according to the NCI CTCAE v4.03 definition.
• In Part I, subjects still have to undergo at least 1 planned cycle with capecitabine monotherapy.
• In Part II, subjects still have to undergo at least 2 planned cycles with capecitabine monotherapy.

Exclusion Criteria

• Are younger than 18 years.
• Use of other chemotherapies for the treatment of cancer except trastuzumab (Herceptin®) or bevacizumab (Avastin®).
• Diagnosis of PPES grade 1 in any hand or foot according to the NCI CTCAE v4.03 definition for more than 2 cycles previously to inclusion in this clinical study.
• Have neurologic symptoms greater than grade 1, which under the criteria of the clinician could interfere with PPES diagnosis or study treatment (e.g. hands or feet neuropathy).
• Have any dermatologic condition that in the opinion of the investigator may affect hands or feet or may complicate evaluation during study treatment (e.g. neurodermatitis, psoriasis, etc).
• Have onycholysis with a non-stable grade 1 or onycholysis greater than grade 1 (nail loss, NCI CTCAE v4.03 criteria) which in the assessment of the clinician could interfere with PPES diagnosis or study treatment.
• Need to use other emollient creams or other topical treatments in hands and/or feet during the study.
• Are receiving radiotherapy.
• Have received topical corticosteroids in hands or feet 7 days prior to planned inclusion in the study.
• Are participating in any other investigational studies for the treatment of PPES.
• Have participated in any other investigational studies for the treatment of PPES, or received an experimental therapeutic procedure, considered to potentially interfere with the study in the 4 weeks preceding Day 1.

The above is not a complete list of eligibility criteria. Please see your study doctor for more information.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cromsource

INDUSTRY

Sponsor Role: collaborator

Advancell - Advanced In Vitro Cell Technologies, S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr. A. Awada

Role: PRINCIPAL_INVESTIGATOR

Jules Bordet Institute

Locations

Imelda

Bonheiden, , Belgium

Institute Jules Bordet

Brussels, , Belgium

AZ Maria Middelares

St-Niklaas, , Belgium

Iniversitätsklinikum Hamburg Eppendorf

Hamburg, , Germany

OncoResearch Lerchenfeld UG

Hamburg, , Germany

Klinikum Offenbach GmbH

Offenbach, , Germany

Prosper Hospital

Recklinghausen, , Germany

IRCCS - Istituto Europeo di Oncologia (IEO) di Milano

Milan, Dr. Franco Nolè, Italy

A.O. Universitaria Policlinico S.Orsola-Malpighi di Bologna

Bologna, , Italy

Azienda Ospedaliero Universitaria "Maggiore Della Carità" di Novara

Novara, , Italy

Azienda Ospedaliero Universitaria di Sassari

Sassari, , Italy

Institut Català d'Oncología

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Puerta de Hierro

Majadahonda, Madrid, Spain

HGU Alicante

Alicante, , Spain

Hospital del Mar

Barcelona, , Spain

Hospital Vall d'Hebron

Barcelona, , Spain

Complejo Hospitalario Regional Reina Sofia

Córdoba, , Spain

Hospital General de Elche

Elche, , Spain

Hospital Clínic i Provincial

Madrid, , Spain

Hospital Gregorio Marañón

Madrid, , Spain

HGU La Paz

Madrid, , Spain

Hospital Ramón y Cajal

Madrid, , Spain

Hospital de Navarra

Pamplona, , Spain

Hospital de Torrevieja

Torrevieja, , Spain

Institut Valencià d'Oncologia

Valencia, , Spain

Hospital Miguel Servet

Zaragoza, , Spain

Countries

Belgium; Germany; Italy; Spain

Other Identifiers

ATH008-CLN02

Identifier Type: -

Identifier Source: org_study_id